Related Experiment Video

Updated: Aug 11, 2026

A Technique for Serial Collection of Cerebrospinal Fluid from the Cisterna Magna in Mouse
08:08

A Technique for Serial Collection of Cerebrospinal Fluid from the Cisterna Magna in Mouse

Published on: November 10, 2008

Cerebrospinal fluid C3a increases with age, but does not increase further in Alzheimer's disease

D A Loeffler1, C M Brickman, P L Juneau

  • 1Clinical Neuroscience Program, Sinai Hospital, Detroit, MI 48235, USA.

Neurobiology of Aging
|December 9, 1997
PubMed

Insights

Alzheimer's disease (AD) cerebrospinal fluid (CSF) shows increased complement proteins C3a and SC5b-9 in older adults, but not specifically in AD patients compared to age-matched controls.

Area of Science:

  • Neuroscience
  • Immunology
  • Biochemistry

Background:

  • Complement activation is implicated in Alzheimer's disease (AD) pathogenesis.
  • Cerebrospinal fluid (CSF) C1q levels are reduced in AD patients.

Purpose of the Study:

  • To investigate alterations in CSF concentrations of complement proteins C3a and SC5b-9 in Alzheimer's disease.
  • To compare these levels between probable AD patients, normal aged controls, and normal younger controls.

Main Methods:

  • Measurement of C3a and SC5b-9 concentrations in CSF samples.
  • Statistical analysis comparing protein levels across three groups: probable AD (n=19), aged controls (n=11), and younger controls (n=15).

Main Results:

  • C3a levels were significantly higher (threefold) in both AD and aged control groups compared to younger controls.
  • SC5b-9 levels showed a twofold increase in AD patients compared to younger controls, but not significantly different from aged controls.
  • CSF concentrations of C3a and SC5b-9 did not significantly differ between AD patients and age-matched normal controls.

Conclusions:

  • Elevated C3a and SC5b-9 in CSF are associated with aging, not specifically with Alzheimer's disease.
  • Increased complement protein levels in aged individuals may reflect general complement activation, CNS production, or blood-brain barrier leakage.
  • These findings suggest localized brain complement activation in AD may not translate to detectable systemic CSF level changes compared to normal aging.

More Related Videos

Quantitative 3D In Silico Modeling (q3DISM) of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease09:33

Quantitative 3D In Silico Modeling (q3DISM) of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Published on: December 26, 2016

An Improved Method for Collection of Cerebrospinal Fluid from Anesthetized Mice06:40

An Improved Method for Collection of Cerebrospinal Fluid from Anesthetized Mice

Published on: March 19, 2018

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Cerebral Edema ll: Pathophysiology01:22

Cerebral Edema ll: Pathophysiology

Vasogenic edema is a major form of cerebral edema characterized by abnormal accumulation of fluid in the brain’s extracellular space due to disruption of the blood–brain barrier (BBB). The BBB is a specialized structure composed of endothelial cells connected by tight junctions, supported by astrocytic endfeet and a basement membrane. Under normal conditions, it tightly regulates the movement of ions, proteins, and solutes between the bloodstream and brain parenchyma. When this barrier loses...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...